drugset / Trial / NCT02783547
Combination Therapy of SyB C-1101 and Azacytidine in Patients With Myelodysplastic Syndrome
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1 clinical trial to evaluate the tolerability of a combination therapy of SyB C-1101 (rigosertib sodium) and Azacytidine and to determine the recommended dose of SyB C-1101for Phase 2 trial in patients with myelodysplastic syndrome.
Timeline
- Start
- 2015-12
- Primary completion
- 2017-06
- Completion
- 2017-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | rigosertib | Small molecule | 560 mg | Oral |
| Subject | rigosertib | Small molecule | 840 mg | Oral |
| Background | Azacitidine | Other / unclassified | 75 mg/m2 | Subcutaneous |